Autolus Announces Closing of Public Offering
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering of American Depositary Shares (“ADSs”) in the United States. Autolus sold 7,250,000 ADSs representing 7,250,000 ordinary shares at a public offering price of $11.00 per ADS. Autolus has also granted the underwriters a 30-day option to purchase up to an additional 1,087,500 ADSs at the public offering price, less underwriting discounts and commissions.
